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Although use of non-steroidal anti-inflammatory drugs (NSAIDs) 
generally decreases colorectal cancer (CRC) risk, inherited 
genetic variation in inflammatory pathways may alter their 
potential as preventive agents. We investigated whether varia-
tion in prostaglandin synthesis and related pathways influences 
CRC risk in the Colon Cancer Family Registry by examin-
ing associations between 192 single nucleotide polymorphisms 
(SNPs) and two variable nucleotide tandem repeats (VNTRs) 
within 17 candidate genes and CRC risk. We further assessed 
interactions between these polymorphisms and NSAID use on 
CRC risk. Using a case-unaffected-sibling-control design, this 
study included 1621 primary invasive CRC cases and 2592 sib-
ling controls among Caucasian men and women aged 18–90. After 
adjustment for multiple comparisons, two intronic SNPs were 
associated with rectal cancer risk: rs11571364 in ALOX12 [ORhet/
hzv = 1.87, 95% confidence interval (CI) = 1.19–2.95, P = 0.03] and 
rs45525634 in PTGER2 (ORhet/hzv = 0.49, 95% CI = 0.29–0.82, P 
= 0.03). Additionally, there was an interaction between NSAID 
use and the intronic SNP rs2920421 in ALOX12 on risk of CRC 
(P = 0.03); among those with heterozygous genotypes, risk was 
reduced for current NSAID users compared with never or former 
users (ORhet = 0.60, 95% CI = 0.45–0.80), though not among those 
with homozygous wild-type or variant genotypes. The results of 
this study suggest that genetic variation in ALOX12 and PTGER2 
may affect the risk of rectal cancer. In addition, this study sug-
gests plausible interactions between NSAID use and variants in 
ALOX12 on CRC risk. These results may aid in the development 
of genetically targeted cancer prevention strategies with NSAIDs.
Introduction
Inflammation has long been recognized as an important contribu-
tor to colorectal cancer (CRC) risk (1–3). For example, chronic 
inflammatory conditions, such as inflammatory bowel disease, are 
associated with increased CRC risk and prior studies suggest that 
both inflammatory bowel disease-associated and sporadic CRC share 
mechanisms linked to inflammation (3–5). Although the exact mecha-
nisms that contribute to this process are still unclear (3,4), inflamma-
tion may enable carcinogenesis by contributing to cell proliferation 
and survival, angiogenesis and genetic mutations (4,6,7). Use of non-
steroidal anti-inflammatory drugs (NSAIDs), which inhibit inflamma-
tion, decreases CRC risk (8–12); however, inherited variation in genes 
that affect NSAID metabolism may alter their potential as preventive 
agents.
NSAIDs inhibit the cyclooxygenase (COX) enzymes, which con-
trol the conversion of arachidonic acid (AA) to prostaglandins and 
thromboxane (Figure 1) (2,12). COX1 and COX2 (encoded by PTGS1 
and PTGS2) are the main targets of traditional NSAIDs (such as aspi-
rin and ibuprofen) as well as COX2-specific inhibitors. They are the 
main enzymes responsible for reducing AA to prostaglandin H2, 
which is metabolized to a substrate for thromboxane synthase, pros-
tacyclin synthase (PGI) and prostaglandin synthase (PG). Via these 
synthases, prostaglandin H2 is metabolized into thromboxane A2, 
PGI2, prostaglandin E2 (PGE2) and prostaglandin D2, which modu-
late important cellular functions by binding to their respective recep-
tors: TP to thromboxane A2, IP to PGI2, EP (EP1-4) to PGE2 and DP 
to prostaglandin D2 (12–14). Arachidonate lipoxygenases (ALOXs) 
convert AA into leukotrienes and other eicosanoids that regulate 
inflammatory processes (15,16). Additionally, eicosanoid levels differ 
between normal and colon cancer tissues, with PGE2 levels increased 
and PGI2 levels decreased in colon cancer samples (17).
Prior studies, including ours, reported associations between poly-
morphisms in genes involved in inflammation pathways and CRC risk 
and mortality (18–24). Likewise, numerous epidemiologic studies 
and randomized trials have shown that NSAID use reduces CRC risk 
and mortality (8–11,25–27). However, as we have shown previously, 
genetic variation in NSAID-metabolizing pathways (upstream and 
downstream) may affect the capacity of NSAIDs to serve as chemo-
preventive agents (28). Therefore, we investigated whether variation 
in genes involved in prostaglandin synthesis or related pathways might 
impact CRC risk. Using data from the population-based Colon Cancer 
Family Registry (CCFR) (29), we assessed whether single nucleo-
tide polymorphisms (SNPs) and variable nucleotide tandem repeats 
(VNTRs) were independently associated with CRC risk and whether 
these associations were modified by pre-diagnostic use of NSAIDs.
Materials and methods
Study population
The study population has been described previously (29). Briefly, cases were 
men and women recruited from six registry centres and aged 18–90 when diag-
nosed with primary invasive CRC from 1998–2002. Cases included probands 
and any affected relatives, and were interviewed within 5 years of diagnosis. 
CRC included distal (left-sided), proximal (right-sided) and not otherwise 
specified colon cancers as well as rectal cancers. Controls were siblings not 
diagnosed with CRC at the time of ascertainment. Individuals whose self-
reported sex did not match that determined by genotyping were excluded, as 
were cases that did not have at least one matched unaffected sibling control. 
Further, this study included only participants ascertained through population-
based recruitment who self-reported as Caucasian, with no known familial 
adenomatous polyposis and no personal history of ulcerative colitis or Crohn’s 
disease. Other racial/ethnic groups and clinic-based populations were excluded 
as sample sizes were too small to examine associations.
Epidemiologic data were collected from CCFR study participants using 
standard questionnaires on demographic characteristics, medical history, 
NSAID use, family history of cancer, smoking history, diet, physical activity, 
height and weight. Blood and tissue samples were collected using standardized 
procedures across CCFR sites and DNA was extracted from peripheral blood 
Abbreviations: AA, arachidonic acid; bp, base pair; ALOX, arachidonate 
lipoxygenase; CI, confidence interval; COX, cyclooxygenase; CRC, colorectal 
cancer; LD, linkage disequilibrium; NSAID, non-steroidal anti-inflammatory 
drug; OR, odds ratio; PGE2, prostaglandin E2; PGI, prostacyclin synthase; SNP, 
single nucleotide polymorphism; VNTR, variable nucleotide tandem repeat.
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leucocytes. Participants were provided a list of common aspirin and non-aspi-
rin NSAIDs brands and reported their average weekly consumption. Current 
NSAID use was defined as use two or more times per week for at least 1 month 
in the 2 years prior to study enrollment. The Institutional Review Boards at 
each CCFR site approved this study and informed consent was obtained from 
all study participants.
Polymorphism selection
We selected a total of 220 candidate and tagging SNPs (tagSNPs) and three 
functional VNTRs in 17 candidate genes involved in prostaglandin synthe-
sis and related pathways. The following genes were included: ALOX12, 
ALOX5, ALOX5AP, CRP, EGFR, GIPC1, HPGD, PARP12, PKN1, PLA2G1B, 
PTGER1, PTGER2, PTGER3, PTGER4, PTGES, PTGIS and TBXAS1. The 
procedure for tagSNP selection has previously been published (30). Briefly, 
using Haploview Tagger on publicly available HapMap 2 data (31), tagSNPs 
were selected based on a pairwise r2 > 0.95, a minor allele frequency >5% and 
distance from the closest SNP of >60 base pairs (bp). Within linkage disequi-
librium (LD) blocks for each gene, the 5′- and 3′-untranslated regions (UTR) 
were extended to include the most up- or downstream SNP (~10 kb upstream 
and 5 kb downstream). In regions of no or low LD, SNPs with a minor allele 
frequency >5% at a density of ~1 per kb were selected from either HapMap 
(31) or dbSNP (32). When we designed the study using HapMap 2 as a refer-
ence panel, tagSNPs genotyped by the CCFR were estimated to cover at least 
80% of the variation in these loci. With the HapMap 3 release, ~50% of these 
loci are covered.
Genotyping assays
SNPs were genotyped using the Illumina BeadXpress GoldenGate at 
Translational Genomics Research Institute (TGen, Phoenix, AZ). Replicate 
aliquots were included for 5% of samples to assess reliability. Concordance 
among duplicates was at least 99.8% for all SNPs. Monomorphic SNPs, 
SNPs with call rates <90% and SNPs with Hardy–Weinberg Equilibrium P 
values < 0.001 among unrelated Caucasian controls were excluded (N SNPs 
excluded = 28), resulting in 192 SNPs available for analysis.
Three VNTRs were also genotyped: the 9-base microsatellite polymor-
phism at nt –3 in the PTGIS (CYP8A1) 5′-untranslated region, which is a 
repeat of 4–7 copies of a putative Sp1 binding site (33), the ALOX5 VNTR 
promoter polymorphism [−176(GGGCGG)2–8], and the ALOX5AP (FLAP) 
poly(A) promoter repeat [−169poly(A)]. The PTGIS VNTR was genotyped by 
GeneScan assay as described previously (34). Briefly, the PTGIS (CYP8A1) 
promoter region was PCR amplified with a fluorescently tagged primer and 
size separated by capillary electrophoresis using an ABI 3130xl Sequence 
Analyzer (Life Technologies). Amplicon length was analysed using Genotyper 
software. The DNA input was 40 ng with a total reaction volume of 5 μl. The 
ALOX5 and ALOX5AP VNTRs were genotyped using GeneScan on an ABI 
3130xl, based on previously published protocols (34,35). Briefly, multiplex 
PCR reactions consisted of 40 ng genomic template DNA, 1.5 mmol/l MgCl2, 
1x PCR Gold Buffer (Applied Biosystems), 0.5 units of Amplitaq Gold 
Polymerase (Applied Biosystems), 200 nmol/l each of oligonucleotide prim-
ers ALOX5sp1-F 5′-6FAM-AGGAA CAGACACC TCGCTG AGGAGAG-3′, 
ALOX5sp1-R 5′GAGCAGCGAGCGCCGGGAGCCTCGGC-3′, -F: 5′ 
VIC-CGTGCTCCTCTGCCAAGCCCTGCTTC- 3′ and ALOX5AP-R02: 5′-
GCTCT GCCTCCAGCTGCACAACCTG-3′, 150 µmol/l each of dATP, dCTP 
and dTTP, 75 µmol/l each of dGTP and 7-deaza-2V-dGTP (Roche Diagnostics 
GmbH, Mannheim, Germany) and 8% (vol/vol) DMSO (Sigma, St Louis, 
MO) in 5 μl. Cycling was as follows: 96°C for 7 min, 30 cycles of: 94°C for 30 
s, 58°C for 30 s, 72°C for 30 s, 72°C for 7 min. The observed 6FAM-labeled 
ALOX5 amplicon lengths ranged from 254 bp (26-bp repeats) to 290 bp (86-bp 
repeats) and VIC-labeled ALOX5AP amplicon was either 212 bp (19A) or 216 
bp (23A). However, we excluded the ALOX5AP VNTR from analysis as it had 
a Hardy–Weinberg Equilibrium P value < 0.001 among Caucasian controls.
Statistical methods
Because colon and rectal cancer could have unique etiological mechanisms, we 
chose a priori to assess separately the association between each polymorphism 
and colon and rectal cancer risk as well as combined CRC risk using condi-
tional logistic regression to compute odds ratios (OR) and 95% confidence 
intervals (CI). Conditional logistic regression was also used to examine inter-
actions between polymorphisms and current NSAID use for CRC, colon and 
rectal cancer risk. For interaction analyses, ORs and 95% CI were computed 
within categories of NSAID use in order to compare genotypes. Likelihood 
ratio tests were used to calculate P values for polymorphism main effects and 
polymorphism–NSAID interactions. Statistical significance of main effects 
was determined using minP permutation tests (36) with 10 000 replications 
to obtain multiple comparison corrected P values. Statistical significance of 
interactions was determined using Bonferroni correction (37). VNTR geno-
types were analysed categorically based on the number of repeats (≥6/≥6, 
<6/≥6 and <6/<6 for the PTGIS repeat and ≥5/≥5, <5/≥5 and <5/<5 for the 
ALOX5 repeat). We used co-dominant models for each polymorphism, except 
where genotype cell counts were <10 in either cases or controls in which case 
we used a dominant model. We did not estimate associations where genotype 
cell counts were less than five after combining heterozygotes and homozygous 
Fig. 1. Prostaglandin synthesis pathway. The COX enzymes COX1 and COX2, which reduce arachidonic acid to prostaglandin H2 (PGH2), are the main targets 
of COX2-specific inhibitors and NSAIDs. PGH2 becomes a substrate for thromboxane, prostacyclin and prostaglandin synthases, which are converted into 
thromboxane A2 (TXA2), PGI2, PGE2 and prostaglandin D2 (PGD2). Arachidonic lipoxygenesases and hydroperoxides (HPETEs) convert arachidonic acid into 
leukotrienes and other inflammation-mediating eicosanoids.
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minor allele carriers. All models used sibling kinship as a matching variable 
and were adjusted for continuous linear age and sex. Polymorphism–NSAID 
interactions were further adjusted for body mass index (continuous), cigarette 
smoking in pack–years (continuous) and physical activity [categorized from 
average metabolic equivalent of task hours into inactive (0–6), less active 
(6.1–20), active (20.1–44) and very active (>44)]. All analyses were performed 
using SAS 9.3 or R version 2.13.2.
Results
Distributions of demographic characteristics were mostly similar by 
case–control status (Table I). Although slightly more cases than con-
trols were male, there were no substantial differences by age, study 
center, NSAID use, physical activity, body mass index or cigarette 
smoking.
After correcting for multiple comparisons, no polymorphisms 
reached statistical significance for associations with CRC or colon 
cancer risk. However, two SNPs were associated with rectal cancer 
risk: rs11571364 in ALOX12 and rs45525634 in PTGER2 (Table II). 
Individuals carrying the variant allele of rs11571364 (G>A) in 
ALOX12 were at an almost 90% increased risk of rectal cancer (ORhet/
hzv = 1.87, 95% CI = 1.19–2.95). In contrast, those carrying the vari-
ant allele of rs45525634 (G>T) in PTGER2 had an ~50% decreased 
risk of rectal cancer (ORhet/hzv = 0.49, 95% CI = 0.29–0.82). All other 
associations with CRC, colon and rectal cancer risk are presented in 
Supplementary Table 1, available at Carcinogenesis Online.
Although current NSAID use was not associated with a statisti-
cally significant reduced risk of CRC in this study population when 
compared with never or former use (OR = 0.86, 95% CI = 0.71–1.04, 
P  =  0.11), after correcting for multiple comparisons we observed 
an interaction (P = 0.03) between NSAID use and the intronic SNP 
rs2920421 (G>A) in ALOX12 on the risk of CRC (Table III). Among 
those with heterozygous genotypes for rs2920421, current NSAID 
users had an ~40% decreased risk of CRC (ORhet = 0.60, 95% CI 
= 0.45–0.80) compared with never or former users, whereas this 
association was null among individuals with homozygous wild-type 
genotypes (ORhzw = 1.12, 95% CI = 0.86–1.46) and not significantly 
reduced among homozygous variant genotypes (ORhzv = 0.83, 95% 
CI = 0.45–1.51). We observed similar effect sizes for colon and rectal 
cancer risk separately, though these associations were not statistically 
significant after multiple comparison adjustment (Supplementary 
Table  2a and b, available at Carcinogenesis Online). Results for 
all other potential interactions for CRC, colon and rectal cancer 
risk are presented in Supplementary Table  2a and b, available at 
Carcinogenesis Online.
Discussion
We examined the association between CRC risk, NSAID use, and 
192 candidate and tagSNPs and two VNTRs within 17 candidate 
genes involved in prostaglandin synthesis and related pathways. We 
observed that variants in two intronic SNPs, rs11571364 in ALOX12 
and rs45525634 in PTGER2, were associated with rectal cancer risk. 
Our observation that these SNPs were associated with rectal can-
cer risk and not colon or combined colorectal cancer risk reflects 
the likelihood that colon and rectal cancer have unique etiological 
mechanisms (38,39). A post-hoc case–case comparison suggested a 
marginally significant difference in relative risk between colon and 
rectal cancers for rs11571364 in ALOX12 (P = 0.05), yet less so for 
rs45525634 in PTGER2 (P = 0.09) (data not shown). We observed an 
interaction between current NSAID use and rs2920421 in ALOX12 
in relation to risk of CRC. A post-hoc case–case comparison of the 
interaction between this SNP and current NSAID use indicated there 
was no difference in the association between colon and rectal can-
cers (P = 0.20) (data not shown). The SNPs for which we observed 
statistically significant associations in ALOX12 (rs2920421 and 
rs11571364) and PTGER2 (rs45525634) were not in high LD with 
any of the other genotyped SNPs within these genes among controls 
(all pairwise r2 < 0.65).
We observed that current NSAID users had a decreased risk of CRC 
compared with never or former users among those with heterozygous 
genotypes for rs2920421 in ALOX12. We conducted a post-hoc anal-
ysis with NSAID use categorized as never, former and current. When 
compared with never users the risk of CRC was reduced among cur-
rent NSAID users (OR = 0.88, 95% CI = 0.72–1.07) and null among 
former users (OR = 1.07, 95% CI = 0.88–1.29), though the over-
all association between NSAID use and CRC risk was not statisti-
cally significant (global P = 0.22). When examining the interaction 
between NSAID use and rs2920421, we observed that current NSAID 
users with heterozygous genotypes had an ~40% decreased risk of 
CRC (ORhet = 0.61, 95% CI = 0.45–0.83) while there was no associa-
tion for former NSAID users with heterozygous genotypes (ORhet = 
1.07, 95% CI = 0.79–1.44) when compared with never users. Among 
individuals with homozygous wild-type genotypes, this association 
was null when comparing former users (ORhzw = 1.14, 95% CI = 
0.86–1.50) and current users (ORhzw = 1.17, 95% CI = 0.89–1.54) to 
never users. Among individuals with homozygous variant genotypes, 
this association was modestly, although not statistically significantly, 
reduced when comparing former users (ORhzv = 0.84, 95% CI =  
0.46–1.52) and current users (ORhzv = 0.79, 95% CI = 0.43–1.47) to 
never users. Overall, our results suggest that the expected protective 
association with NSAIDs is present only among subjects with variant 
genotypes. Variants in ALOX12 could modify the effect of NSAIDs 
on CRC risk, with this association likely being driven by current 
NSAID use. However, larger sample sizes are needed to verify these 
results.
ALOX12 is one of three main lipoxygenases responsible for 
mediating inflammatory responses and converting AA into leukot-
rienes and other eicosanoids (16,40–42). Further, ALOX12 is up-
regulated in CRC tumour tissues and promotes vascular endothelial 




N % N %
Age
 Years (mean ± SD) 53.9 ± 11.7 53.6 ± 10.8
Sex
 Male 1158 44.7 833 51.4
Center
 Ontario 499 19.3 301 18.6
 Los Angeles 461 17.8 335 20.7
 Australia 594 22.9 327 20.2
 Hawaii 8 0.3 7 0.4
 Mayo 474 18.3 251 15.5
 Seattle 556 21.5 400 24.7
NSAID use
 Never/former 1974 76.8 1265 78.3
 Current 595 23.2 351 21.7
Physical activity
 Inactive 598 24.5 383 24.8
 Less active 702 28.8 433 28.0
 Active 582 23.9 389 25.2
 Very active 558 22.9 340 22.0
BMI
 kg/m2 (mean ± SD) 26.7 ± 5.2 27.2 ± 5.5
Cigarette smoking
 Pack–years (mean ± SD) 11.7 ± 19.4 12.9 ± 19.7
Tumor site
 Colon
  Right — — 542 33.4
  Left — — 466 28.7
  NOS — — 76 4.7
 Rectal — — 537 33.1
BMI, body mass index; NOS, not otherwise specified.
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growth factor production in tumour stroma, which contributes to 
angiogenesis and the motility of cancer cells (43,44). Of interest, 
the SNP in ALOX12 for which we observed an interaction between 
current NSAID use and CRC risk (rs2920421) is in high LD 
(r2 = 1.0) with another SNP (rs2440129) that has been associated 
with microRNA expression levels in adipose tissue and body mass 
index in genome-wide association studies (45). Although genome-
wide association studies have not observed associations between 
CRC risk and variants in ALOX12, results from previous candidate-
gene studies suggest plausible associations. In a recent case–con-
trol study of colon and rectal cancer risk (N colon cases = 1574, 
N rectal cases = 791, N controls = 2,969), there was evidence that 
fatty acid intake and aspirin use modified the associations between 
two variants in ALOX12, the intronic SNP rs11571339 and the 
coding SNP rs312462 (L634L), and the risk of rectal cancer (46). 
Another study of 2300 Chinese CRC cases and controls observed 
that the coding SNP rs1126667 (G261A) in ALOX12 was associ-
ated with an increased risk of CRC, and further observed an inter-
action between this SNP and rs689466 in PTGS2 on CRC risk 
(47). A study assessing the association of variants in ALOX12 and 
ALOX5 with CRC risk among 162 cases and 211 controls reported 
a borderline association between rs1126667 and CRC risk (48). 
However, two other studies reported no association between this 
SNP and CRC risk (15,49). In the current study, rs1126667 was 
associated with a decreased risk of CRC (ORAA versus wtGG = 0.71, 
95% CI 0.55–0.93); however, this association was not statistically 
significant after correcting for multiple comparisons. Nonetheless, 
our study presents novel results for variants in ALOX12, as no prior 
studies have reported an association between rs11571364 and rectal 
cancer risk or an interaction between NSAID use and rs2920421 on 
the risk of CRC.
This study is also the first to report an association between rectal 
cancer risk and the intronic SNP rs45525634 in PTGER2. Based on 
data from the Encyclopedia of DNA Elements (ENCODE) Consortium 
(50), rs45525634 may regulate transcription. PTGER2 encodes the 
receptor EP2 for PGE2 (21,51–55), which is thought to be critical in 
CRC development as it promotes angiogenesis as well as the survival, 
motility and invasiveness of cancer cells (52–57). In a recent study, 
overexpression of PTGER2 was associated with high microsatellite 
instability in CRC tumours (58). EP2 also plays an important role in 
colorectal carcinogenesis, having been shown to contribute to intes-
tinal polyps and to affect tumour growth in mice (59–61). Genome-
wide association studies have not identified SNPs in PTGER2 as 
associated with CRC risk, though some candidate-gene studies have 
reported associations. In a study of 1225 CRC cases and 2032 con-
trols, the intergenic SNP rs17831718 was associated with a roughly 
30% decreased risk of CRC (OR = 0.73, 95% CI: 0.58–0.91) (62). 
Moreover, this study observed a statistically significant inverse associ-
ation (P = 0.006) between CRC risk and the PTGER2 GGG haplotype 
based on the SNPs rs17831718, rs17125362 and rs1254580. Another 
recent large study observed an increased polyp risk for rs17125318, an 
intergenic SNP close to PTGER2 (P = 0.008) (63). In our prior study 
examining adenoma cases and polyp-free controls, we observed the 
intronic SNP rs33993630 in PTGER2 to be associated with a reduced 
risk of colorectal adenoma (OR = 0.71, 95% CI: 0.52–0.99) (21). In 
the present study, those carrying the variant allele for rs33993630 had a 
Table II. Statistically significanta associations between polymorphisms and rectal cancer risk
Rectal cancer
Controls Cases ORb 95% CI Pc
N % N %
ALOX12
 rs11571364 G/G 762 87.8 429 83.3 ref — 0.03
 Intron G/A or 
A/A
106 12.2 86 16.7 1.87 1.19–2.95
PTGER2
 rs45525634 G/G 764 87.9 468 91.2 ref — 0.03
 Intron G/T or TT 105 12.1 45 8.8 0.49 0.29–0.82
aStatistical significance considered a minP P value ≤ 0.05.
bAdjusted for continuous linear age and sex.
cMultiple comparisons corrected P value from a minP permutation test with 10 000 replications.
Table III. Statistically significanta polymorphism–NSAID use interactions and colorectal cancer risk
NSAID use
Never/former Currentb Pd
Controls Cases ORc 95% CI Controls Cases ORc 95% CI
ALOX12
 rs2920421 G/G 920 586 ref — 257 183 1.12 0.86–1.46 0.03
 Intron G/A 818 541 ref — 268 132 0.60 0.45–0.80
A/A 203 124 ref — 59 29 0.83 0.45–1.51
 rs2920421e G/G 920 586 ref — 257 183 1.12 0.86–1.46 0.03
 Intron G/A 818 541 1.16 0.95–1.43 268 132 0.70 0.51–0.95
A/A 203 124 1.09 0.77–1.53 59 29 0.90 0.49–1.65
BMI, body mass index.
aStatistical significance considered a Bonferroni-adjusted P value ≤ 0.05.
bCurrent NSAID use defined as use two or more times per week for at least 1 month in the 2 years prior to study enrollment.
cAdjusted for continuous linear age, BMI, and smoking as well as sex and physical activity (categorized from average MET hours into inactive, less active, active 
and very active).
dBonferroni-adjusted interaction P value.
eResults presented using a common reference group.
2124
Genetic variation, NSAID use and CRC risk
reduced risk of rectal cancer (OR = 0.49, 95% CI: 0.29–0.82, P = 0.02); 
however, this association was not statistically significant after correct-
ing for multiple comparisons (P = 0.07). Likewise, we observed no 
evidence of an interaction between rs33993630 and NSAID use on 
CRC, colon or rectal cancer risk.
This study is the first to examine associations and NSAID use 
interactions between CRC risk and the functional VNTRs in ALOX5 
and PTGIS. Our previous study observed an increased risk of colo-
rectal polyps associated with the PTGIS VNTR (OR<6/<6 versus 6/6 = 
1.90, 95% CI: 1.09–3.30), though not with the ALOX5 VNTR (34). 
In the current study, neither the ALOX5 nor PTGIS VNTR was asso-
ciated with CRC risk, nor did we observe evidence of interactions 
with NSAID use.
Although we observed an association only between rectal cancer 
risk and variants in ALOX12 and PTGER2, previous studies have 
shown variants in other genes involved in prostaglandin synthesis and 
related pathways to be associated with CRC risk. For example, prior 
studies have suggested associations between CRC risk and variants 
in the cytokines IL6 and TNF (64–66) as well as PTGS2 (COX2), 
including rs689466, rs20417 and rs4648298 (47,67). Further, a prior 
study of variants in ALOX5, ALOX12, PTGS1 and PTGS2 observed 
two SNPs both in the flanking 5′-untranslated region of ALOX5, 
rs6413416 and rs4986832, to be associated with colon cancer risk 
among Caucasians (15). We assessed 21 SNPs in ALOX5 in this study, 
including rs4986832, but none was significantly associated with CRC, 
colon or rectal cancer risk after adjustment for multiple comparisons.
There were some potential limitations to this study. We observed 
that current NSAID use was associated with a modestly and non-sig-
nificantly reduced risk of CRC compared with never or former use (OR 
= 0.86, 95% CI: 0.71–1.04; P  = 0.11); therefore, we may have been 
limited in our ability to detect interactions between current NSAID use 
and the polymorphisms analysed. It is possible that we missed relevant 
variation in the genes we examined due to incomplete coverage, though 
this is unlikely given our thorough candidate and tagSNP approach. We 
may also have missed variation by not examining deletions, copy num-
ber variation or additional variants in repeat regions; however, we were 
unable to examine some of this variation given our genotyping methods. 
Finally, although assays may have misclassified or failed to detect vari-
ation in the genes examined for this study, this was not likely an issue 
since we had high concordance among duplicate samples.
There were several strengths to this study. Our use of a combined 
candidate and tagSNP approach enabled comprehensive coverage of 
most of our genes of interest, including an assessment of VNTRs in 
ALOX5 and PTGIS. By using data from the CCFR, this study had 
large numbers of cases and controls as well as access to extensive 
data on demographic and lifestyle factors, including NSAID use. 
These design features allowed us to examine the association between 
polymorphism–NSAID interactions and CRC, colon and rectal cancer 
risk. Further, although this study made a number of comparisons, all 
results were interpreted after correcting for multiple comparisons.
Results from this study suggest that genetic variation in ALOX12 
and PTGER2 may be associated with the risk of rectal cancer. In addi-
tion, this study suggests that current use of NSAIDs may interact with 
variants in ALOX12 to modify CRC risk. As these results may aid in 
the development of genetically targeted cancer prevention strategies 
with NSAIDs, further studies are warranted that examine the asso-
ciation between CRC risk, NSAID use, and polymorphisms in genes 
involved in prostaglandin synthesis and related pathways.
Supplementary material
Supplementary Tables 1 and 2 can be found at http://carcin. 
oxfordjournals.org/
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